Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ ) 0.4244 -0.0034 (-0.79%) Streaming Delayed Price Updated: 3:59 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mainz Biomed N.V. - Ordinary Shares < Previous 1 2 3 4 5 6 7 8 9 Next > What 5 Analyst Ratings Have To Say About Mainz Biomed September 26, 2023 Via Benzinga AI To Revolutionize Clinical Trials And Diagnostics September 22, 2023 With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference September 20, 2023 From Mainz BioMed NV Via GlobeNewswire Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session September 13, 2023 Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of... Via Benzinga Where Mainz Biomed Stands With Analysts June 01, 2023 Via Benzinga Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention September 13, 2023 By the words of Dr. Ruediger Dahlke, cancer is a caricature of today’s modern society as it reflects the dark side ‘growth’. Our civilization is clearly more on the dark side of growth with technology... Via Benzinga Why Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket September 13, 2023 Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares rose 38.7% to $0.1713 in pre-market trading. Shares of Avalo Therapeutics jumped over 45% on Tuesday after the company agreed to divest AVTX-800... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday September 13, 2023 It's time for another dive into the biggest pre-market stock movers as we check out all the shares worth watching on Wednesday! Via InvestorPlace Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81% September 13, 2023 From Mainz BioMed NV Via GlobeNewswire 10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar September 06, 2023 --News Direct-- Via News Direct Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle September 05, 2023 Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'... Via Benzinga Exposures COVID-19 10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar September 05, 2023 The WHO reports that colorectal cancer is the second most fatal cancer around the world. Via Benzinga Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market September 05, 2023 From Mainz BioMed NV Via GlobeNewswire Second Most Fatal Cancer In U.S. May Face A Big Fight From Mainz Biomed’s Non-Invasive Test; (NASDAQ: MYNZ) Is Making Early Detection Possible August 30, 2023 --News Direct-- Via News Direct Second Most Fatal Cancer In U.S. May Soon Face A Challenger: Mainz Biomed's (NASDAQ: MYNZ) Early Detection Tech August 29, 2023 Colorectal cancer is the third most common cancer worldwide, and although the majority of colorectal cancer cases have historically occurred in individuals aged 45 and older, it is increasingly... Via Benzinga Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference August 29, 2023 Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland August 22, 2023 Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland From Mainz BioMed NV Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session August 18, 2023 Via Benzinga Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update August 15, 2023 From Mainz BioMed NV Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Pre-Market Session August 14, 2023 Via Benzinga Why US Steel Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket August 14, 2023 Gainers AGBA Group Holding Limited (NASDAQ: AGBA) shares surged 49.4% to $1.31 in pre-market trading after the company reported a 325% year-over-year growth in its second-quarter revenue. Via Benzinga Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom August 01, 2023 Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Announces Collaboration with Fugene Genetics in Israel July 18, 2023 Israel has one of the highest screening compliance rates in the world with over one million people being screened each year From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Secures up to $50M in New Funding June 29, 2023 Provides option to access capital to support commercial and clinical programs From Mainz BioMed NV Via GlobeNewswire Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain June 28, 2023 The Company’s innovative CRC screening test will be showcased at booths 105A and 105B in cooperation with partner lab, Inicio-Instituto de Microecología From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Expands into Romania Through Partnership with Bioclinica June 20, 2023 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Expands Commercial Footprint into Poland May 31, 2023 Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today Via PressReach Topics Death Exposures Death Being Overweight or Obese Increases Risk of Developing Colorectal Cancer May 31, 2023 Maintaining a healthy weight is important for general health, but growing evidence reveals obesity’s role in the development of chronic illnesses and even deadly cancers. Obesity is one of the most... Via PressReach Mainz Biomed Expands Commercial Footprint into Poland May 31, 2023 From Mainz BioMed NV Via GlobeNewswire BioNTech’s mRNA Vaccine Shows Early Potential Against Pancreatic Cancer May 24, 2023 One of the most stubborn, deadly cancers is pancreatic cancer. What if individualized mRNA vaccinations could support the immune system’s defense? One of the deadliest forms of cancer around,... Via PressReach < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.